Top Ten most popular articles on Pharmafile.com this week
December 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten
As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration
December 13, 2019Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma
Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
FDA U-turns to approve Sarepta’s Vyondys 53 in Duchenne muscular dystrophy
December 13, 2019Medical Communications, Sales and Marketing FDA, Vyondys 53, pharma, sarepta
The FDA has surprised industry pundits by choosing to approve Sarepta’s Vyondys 53 under an accelerated pathway for the treatment …
Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer
December 12, 2019Business Services Journal of Medicine, Novartis, menopause
Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …
Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer
December 12, 2019Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
Election Day 2019: Where do the two frontrunners stand on the NHS?
December 12, 2019Business Services Boris, Boris Johnson, Corbyn NHS, Donald Trump, Jeremy Corbyn, NHS
The UK goes to the polls today, for the fourth election of the decade and the third since 2015.Despite the …
Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease
December 12, 2019Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales
Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …
China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer
December 12, 2019Sales and Marketing AstraZeneca, Imfinzi, pharma
AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …
New NAFTA terms put hold on Canadian drug prices
December 11, 2019Research and Development, Sales and Marketing Canada, NAFTA, US, pharma
NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …
Multiple sclerosis market to be worth $32.9bn in 2028
December 11, 2019Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma
The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns
December 11, 2019Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma
It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …
27,000 chickens to be culled after UK bird flu outbreak
December 11, 2019Research and Development Bird Flu, Chicken Flu, Swin Flu, influenza, influenza b
A chicken farm in Suffolk has been confirmed by the British government to have cases of bird flu. 27,000 birds …
Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia
December 11, 2019Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma
Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …
Takeda commits to advancing treatments for rare bleeding disorders and cancer
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
MSD set to acquire ArQule in deal worth up to $2.7 billion
December 10, 2019Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma
MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …
Sanofi to move away from diabetes and cardiovascular, as company shakeup continues
December 10, 2019Manufacturing and Production ASH 19, Sanofi, Sanofi Diabetes, Sanofi Insulin, diabetes, insulin
Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the …
South Korea jails executives for their role in Samsung Biologics fraud
December 10, 2019Manufacturing and Production Samsung phones, Sanofi, Sanofi Diabetes, South Korea Healthcare System, South Korea Samsung, diabetes, inhaled insulin, insulin, south korea
Three executives of Samsung Electronics have been sentenced to jail for their role in committing fraud at its biotech affiliate …
Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma
Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …
Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels
December 9, 2019Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology
Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …
Johnson & Johnson to support Rwanda’s preparations against Ebola outbreak
December 9, 2019Sales and Marketing Ebola, Ebola Guniea, Ebola virus
Johnson & Johnson will provide up to 200,000 Ebola vaccines to the Republic of Rwanda, through its pharmaceutical subsidiary Janssen. …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
